Importantly, higher levels of the mean CXXC5 expression predict a poor overall survival only in luminal patients while the expression levels of CXXC5 are not prognostic in HER2+ or Basal-like subtypes (Fig. 5f, Supplementary Fig. S5), further supporting its clinical relevance to ER+ breast cancer. This evidence concerns the gene CXXC5 and breast cancer.